Inhaled anticholinergic therapy: Applied pharmacology and interesting developments

Current Opinion in Investigational Drugs

Volumn 2, Issue 1, 2001, Pages 53-58

  Witek T J , Jr ^a   Disse, B ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Anticholinergic; Asthma; Bronchodilator; COPD; Ipratropium; Tiotropium

Indexed keywords

ANTIASTHMATIC AGENT; ATROPINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; IPRATROPIUM BROMIDE; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

ANTICHOLINERGIC EFFECT; ASTHMA; CHEMICAL MODIFICATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DOSE CALCULATION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG INDUCED DISEASE; DRUG MECHANISM; HISTORY OF MEDICINE; HUMAN; REVIEW; SMOKING; STRUCTURE ANALYSIS;

ADMINISTRATION, INHALATION; ANIMALS; CHOLINERGIC ANTAGONISTS; CLINICAL TRIALS; HUMANS; IPRATROPIUM; SCOPOLAMINE DERIVATIVES;

EID: 0035152050     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. History of anticholinergic treatment in airways disease
2. Atropine cigarettes in asthma emphysema
3. Anticholinergic, antimuscarinic bronchodilators
4. Ipratropium bromide
5. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease
6. Optimal assessment and management of chronic obstructive pulmonary disease (COPD)
7. Management of chronic obstructive pulmonary disease
8. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma
9. Ipratropium bromide (Atrovent Nasal Spray) reduces the nasal response to methacholine
10. Safety and tolerability of supra-therapeutic doses of inhaled ipratropium (TIO)
11. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung
12. Muscarinic pharmacology of the airways
13. The efficacy and safety of combination bronchodilator therapy
14. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone
15. Efficacy of salmeterol xinafoate in the treatment of COPD
16. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium
17. A novel long-acting anticholinergic bronchodilator
18. Effect of BA679 BR. A novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways
19. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: A pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD)
20. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva™) in stable chronic obstructive pulmonary disease
21. The spirometric efficacy of once daily dosing with tiotropium in stable COPD: A 13-week multi-center trial
22. A randomised controlled comparison of tiotropium and ipratropium in the treatment of COPD
23. Tiotropium (Spiriva™): One year bronchodilator efficacy established with once daily dosing in COPD patients
24. Superior bronchodilator effects of tiotropium (TIO) vs. ipratropium (IB) in COPD over a one year clinical trial
25. Tiotropium (Spiriva™), a new long-acting anticholinergic bronchodilator, improves dyspnea in patients with COPD
26. Improvement in perceived dyspnea in COPD patients receiving tiotropium (TIO) vs. ipratropium (IB)
27. Tiotropium (Spiriva™) improves health status in patients with COPD
28. Tiotropium (TIO): Improved quality of life compared to ipratropium (IB) in patients with COPD
29. Tiotropium (TIO) reduces the incidence of COPD exacerbations compared to ipratropium (IB)